

## Who can administer

May be administered by registered competent doctor or nurse

## Important information

- **Reserve antimicrobial:** Restricted for indications in the antimicrobial prescribing guidelines, or following approval by microbiology/infectious diseases
- Isavuconazole is usually administered as **six loading doses** followed by a less frequent maintenance dose. Double check the correct dose is prescribed
- **QT-interval** shortening possible - refer to **SPC**
- **There are numerous important interactions** - check BNF or **current SPC**
- Consider **intravenous to oral switch** as soon as possible as excellent bioavailability (98%)
- See under Monitoring re **Infusion related reactions**

## Available preparations

Cresemba 200mg vial

## Reconstitution

### Water for injections

- Add 5ml water for injections to each 200mg vial
- **Dilute further prior to administration**

## Infusion fluids

Sodium chloride 0.9% or Glucose 5%

## Methods of intravenous administration

**Important: Low pH-** Consider using largest vein possible and monitor patient closely for phlebitis/extravasation (ref 2)

### Intermittent Intravenous infusion

- Add 200mg to 250ml infusion fluid
- The diluted solution should be mixed gently, or the bag should be rolled to minimise the formation of particulates. **Unnecessary vibration or vigorous shaking of the solution should be avoided**
- Administer using an in-line filter (0.2µm to 1.2µm) made of polyether sulfone (PES) (eg Braun filter 0.2µm 0409 9303)
- Administer over at least 60 minutes

## Dose in adults

### Loading dose

- Give 200mg every 8 hours for the first 48 hours (ie. **six loading doses**)

## Maintenance dose

- Give 200mg every 24 hours, beginning 12 to 24 hours after the last loading dose
- Duration of therapy should be determined by the clinical response
- For long-term treatment beyond 6 months, the benefit-risk balance should be carefully considered

## Renal impairment

- No dose adjustment is necessary in patients with renal impairment, including patients with end-stage renal disease

## Hepatic impairment

- No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh Classes A/B)
- Isavuconazole has not been studied in patients with severe hepatic impairment. Use in these patients is not recommended unless the potential benefit is considered to outweigh the risks

## Monitoring

- Elevated liver transaminases have been reported in clinical studies of isavuconazole. Elevations in liver transaminases rarely require discontinuation of isavuconazole. Monitoring of hepatic enzymes should be considered, as clinically indicated
- **Infusion related reaction** include hypotension, dizziness, dyspnoea, parasthesia, nausea and headache. Severe cutaneous reactions have also been reported. Stop infusion if this occurs.

## Storage

Store in a refrigerator 2-8°C

## References

- (1) SPC 04/2021
- (2) Medusa guideline on isavuconazole 9th Nov 2021

## Therapeutic classification

Antifungal agent